Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review

References

• Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:281–92.
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Humira Product Label. Available from http://www.rxabbott.com/pdf/humira.pdf. Accessed August 8, 2015.
   Google Scholar
• Amgen Inc. Enbrel Product Label. Available from http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf. Accessed August 8, 2015.
   Google Scholar
• Janssen Biotech Inc. Remicade Product Label. Available from https://www.remicade.com/shared/product/remicade/prescribing-information.pdf. Accessed August 8, 2015.
   Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–90.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–22.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627–32 (discussion 1632).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–72.
   PubMed Web of Science ®Google Scholar
• Costanzo A, Mazzotta A, Papoutsaki M, et al. Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol. 2005;152:187–9.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–12.
   PubMed Web of Science ®Google Scholar
• De Felice C, Mazzotta A, Esposito M, et al. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients’ quality of life. J Dermatolog Treat. 2006;17:355–8.
   PubMed Web of Science ®Google Scholar
• Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598–603.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241–51.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008;159:1177–85.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63:762–8.
   PubMed Web of Science ®Google Scholar
• Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9:928–37.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Paul C, Berardesca E, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168:1080–7.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Kircik L, Callis Duffin K, et al. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2013;69:385–92.
   PubMed Web of Science ®Google Scholar
• Papp KA, Poulin Y, Bissonnette R, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol. 2012;66:e33–45.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatolog Treat. 2006;17:343–52.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Bombardier C, Thorne C, et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J Rheumatol. 2011;38:1355–62.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Rothman KJ, Kricorian G, et al. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol. 2015;72:115–22.
   PubMed Web of Science ®Google Scholar
• Sukal AS, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol. 2006;54:160–64.
   PubMed Web of Science ®Google Scholar
• Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol. 2009;66:490–7.
   PubMed Web of Science ®Google Scholar
• Nozaki K, Silver RM, Stickler DE, et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci. 2011;342:352–55.
   PubMed Web of Science ®Google Scholar
• Solomon AJ, Spain RI, Kruer MC, Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler. 2011;17:1472–87.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15.
   PubMed Web of Science ®Google Scholar
• Mease PJ ,Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702–9.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Bolduc C, Poulin Y, et al. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol. 2010;63:228–34.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163:402–11.
   PubMed Web of Science ®Google Scholar
• Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol. 2010;37:299–310.
   PubMed Web of Science ®Google Scholar
• Gladman DD, ACCLAIM Study Investigators, Sampalis JS, et al. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol. 2010;37:1898–906.
   PubMed Web of Science ®Google Scholar
• Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64:671–81.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147:429–36.
   PubMed Web of Science ®Google Scholar
• Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2011;66:241–51.
   PubMed Web of Science ®Google Scholar
• Papp K, Ho V, Teixeira HD, et al. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study. J Eur Acad Dermatol Venereol. 2012;26:1007–13.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167:658–67.
   PubMed Web of Science ®Google Scholar
• Menter A, Thaçi D, Papp KA, et al. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol. 2015;73:410–9.e6.
   PubMed Web of Science ®Google Scholar
• Berthelot CN, George SJ, Hsu S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol. 2005;53:S260–2
   PubMedGoogle Scholar
• Chung JH, Van Stavern GP, Frohman LP, Turbin RE. Adalimumab-associated optic neuritis. J Neurol Sci. 2006;244:133–6
   PubMed Web of Science ®Google Scholar
• Alexopoulou A, Koskinas J, Soultati A, et al. Acute bilateral phrenic neuropathy following treatment with adalimumab. Clin Rheumatol. 2009;28:1337–40.
   PubMed Web of Science ®Google Scholar
• Ahmed Z, Powell R, Llewelyn G, Anstey A. Chronic inflammatory demyelinating polyradiculoneuropathy complicating anti TNF α therapy for chronic plaque psoriasis. BMJ Case Rep. 2011;2011. DOI: 10.1136/bcr.08.2011.4674.
   Google Scholar
• Mahil SK, Andrews TC, Brierley C, et al. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. J Dermatolog Treat. 2013;24:38–49.
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842–7.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534–42.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–74.
   PubMed Web of Science ®Google Scholar
• Smith CH, Jackson K, Bashir SJ, et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol. 2006;155:160–9.
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35:869–76.
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H, Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59:40–49
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H, Japanese Infliximab Study investigators. Long‐term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38:321–34.
   PubMed Web of Science ®Google Scholar
• Barker J ,Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate‐to‐severe plaque psoriasis: results of an open‐label, active‐controlled, randomized trial (RESTORE1). Br J Dermatol. 2011;165:1109–17.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Poulin Y, Guenther L, et al. Treatment of palmoplantar psoriasis with infliximab: a randomized, double‐blind placebo‐controlled study. J Eur Acad Dermatol Venereol. 2011;25:1402–8.
   PubMed Web of Science ®Google Scholar
• Baranauskaite A, Raffayová H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71:541–8.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kalb RE, Blauvelt A, et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J Am Acad Dermatol. 2011;67:642–50.
   PubMed Web of Science ®Google Scholar
• Yang HZ, Wang K, Jin HZ, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl). 2012;125:1845–51.
   PubMed Web of Science ®Google Scholar
• Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate‐to‐severe plaque psoriasis: results of a randomized, long‐term extension trial (RESTORE2). Br J Dermatol. 2013;168:1325–34.
   PubMed Web of Science ®Google Scholar
• Shear NH, Hartmann M, Toledo-Bahena M, et al. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. Br J Dermatol. 2014;171:631–41.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kalb RE, Langley RG, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13:1441–8.
   PubMed Web of Science ®Google Scholar
• Cisternas M, Gutiérrez M, Jacobelli S. Successful rechallenge with anti-tumor necrosis factor α for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. Arthritis Rheum. 2002;46:3107–8.
   PubMed Web of Science ®Google Scholar
• Ruiz-Jimeno T, Carvajal A, Mata C, Aurrecoechea E. Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab. J Rheumatol. 2006;33:1457–8.
   PubMed Web of Science ®Google Scholar
• Eguren C, Díaz Ley B, Daudén E, et al. Peripheral neuropathy in two patients with psoriasis in treatment with infliximab. Muscle Nerve. 2009;40:488–9.
   PubMed Web of Science ®Google Scholar
• Bebe AC, Harboe KM, Nøjgaard C. [Neurological symptoms following infusion of infliximab]. Ugeskr Laeger. 2012;174:2388–90.
   PubMedGoogle Scholar
• Naruse H, Nagashima Y, Maekawa R, et al. Successful treatment of infliximab-associated immune-mediated sensory polyradiculopathy with intravenous immunoglobulin. J Clin Neurosci. 2013;20:1618–9.
   PubMed Web of Science ®Google Scholar
• Foulkes AC, Wheeler L, Gosal D, et al. Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis. Br J Dermatol. 2014;170:206–9.
   PubMed Web of Science ®Google Scholar
• TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999;53:457–65.
   PubMed Web of Science ®Google Scholar
• Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol. 2004;140:218–25.
   PubMed Web of Science ®Google Scholar
• Lysandropoulos AP, Pasquier RA. Demyelination as a complication of new immunomodulatory treatments. Curr Opin Neurol. 2010;23:226–33
   PubMed Web of Science ®Google Scholar
• Tristano AG. Neurological adverse events associated with anti-tumor necrosis factor α treatment. J Neurol. 2010;257:1421–31.
   PubMed Web of Science ®Google Scholar
• Liu J, Marino MW, Wong G, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med. 1998;4:78–83.
   PubMed Web of Science ®Google Scholar
• Theibich A, Dreyer L, Magyari M, Locht H. Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. Clin Rheumatol. 2013;33:719–23.
   PubMed Web of Science ®Google Scholar
• Bechtel M, Sanders C, Bechtel A. Neurological complications of biologic therapy in psoriasis: a review. J Clin Aesthet Dermatol. 2009;2:27–32.
   PubMedGoogle Scholar
• Mansouri B, Horner ME, Menter A. Tumor necrosis factor-α inhibitor use in psoriasis patients with a first-degree relative with multiple sclerosis. J Drugs Dermatol. 2015;14:876–8.
   PubMed Web of Science ®Google Scholar